Exploration of Pathology Diagnostic Chips in Precision Medicine and Companion Diagnostics

Precision medicine requires more refined pathological information.

Precision medicine emphasizes selecting appropriate management strategies based on individual patient characteristics. Pathological diagnostic chips can provide multi-target molecular information on the basis of tissue morphology, offering references for the formulation of individualized regimens. Compared with traditional single-indicator detection, chip-based tools can analyze multiple protein, gene, or signaling pathway-related markers in parallel within limited samples, helping pathologists and clinical teams understand the molecular phenotype of lesions. It should be emphasized that this information serves only as part of a comprehensive assessment. Clinical decisions need to be combined with imaging, laboratory tests, patient status, and guideline consensus, and a single chip result cannot replace the complete diagnostic and treatment process.

Potential role in companion diagnostic research.

Companion diagnostics are usually developed together with specific therapeutic drugs or treatment regimens to identify populations that may be suitable for a certain type of intervention. Pathological diagnostic chips can serve as screening tools in the early development of companion diagnostics, conducting multi-target validation and sample stratification studies for candidate biomarkers. For example, in tumor samples, researchers can use chips to observe the expression patterns of multiple immune checkpoints or signaling pathway proteins and explore characteristics related to the drug's mechanism of action. After entering the clinical validation stage, relevant tests need to carry out rigorous analytical performance and clinical significance studies in accordance with regulatory requirements. Whether a chip platform can be translated into an approved companion diagnostic product depends on the strength of evidence and the maturity of quality management.

Sample preprocessing and multi-omics integration.

The application effect of pathological diagnostic chips is highly dependent on sample quality. During fixation, embedding, sectioning, and storage of biopsy tissues, surgical resection specimens, or fine-needle aspiration samples, improper handling may lead to antigen loss or nucleic acid degradation, affecting downstream signals. Therefore, in process design, general conditions such as cold ischemia time, fixative type, and fixation duration need to be strictly controlled, and the sample handling trajectory should be recorded. The multiplex data generated by chips can be integrated with genomic, transcriptomic, or proteomic information to form a more complete description of lesion characteristics. During data integration, attention should be paid to batch effects, platform differences, and algorithm transparency to avoid overinterpretation.

Challenges and rational outlook.

Pathological diagnostic chips still face several practical challenges in precision medicine applications: first, standardization, with insufficient comparability of multicenter data; second, sample heterogeneity, as chip spots represent only the local sampling site and may miss spatially heterogeneous information; third, data interpretation, as multi-indicator signals require joint assessment by pathologists and bioinformatics teams; fourth, compliance boundaries, as research use and clinical use cannot be conflated. In the future, with improved microfluidic processing precision, improved stability of antibodies and probes, and the maturation of digital pathology platforms, pathological diagnostic chips are expected to play a more stable auxiliary role in companion diagnostic research and development, pathological quality control, and medical research. Relevant parties should continue to accumulate real-world research data and promote the gradual standardization of the technology's application.